Tumors Sharply Increased after Ceasing Pazopanib Therapy for a Patient with Advanced Uterine Leiomyosarcoma: Experience of Tumor Flare
Pazopanib has activity in patients with soft-tissue sarcoma. We report an advanced uterine leiomyosarcoma case that suddenly worsened after cessation of pazopanib therapy. A 47-year-old woman had a primary uterine leiomyosarcoma tumor and multiple lung metastases, which progressed during her initial...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Case Reports in Obstetrics and Gynecology |
| Online Access: | http://dx.doi.org/10.1155/2017/4801650 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841524660628357120 |
|---|---|
| author | Terumi Tanigawa Shintaro Morisaki Hisanobu Fukuda Shuichiro Yoshimura Hisayoshi Nakajima Kohei Kotera |
| author_facet | Terumi Tanigawa Shintaro Morisaki Hisanobu Fukuda Shuichiro Yoshimura Hisayoshi Nakajima Kohei Kotera |
| author_sort | Terumi Tanigawa |
| collection | DOAJ |
| description | Pazopanib has activity in patients with soft-tissue sarcoma. We report an advanced uterine leiomyosarcoma case that suddenly worsened after cessation of pazopanib therapy. A 47-year-old woman had a primary uterine leiomyosarcoma tumor and multiple lung metastases, which progressed during her initial treatment. In subsequent treatment with pazopanib for 3 months, the sum of her tumor diameters after cessation sharply increased for two weeks. Symptoms such as dyspnea suddenly worsened also. She died of the disease one month after cessation of pazopanib therapy. Given the poor prognosis of recurrent uterine leiomyosarcoma and the rapid tumor enlargement after ending pazopanib therapy, control of this disease is especially important. Therefore, the decision to discontinue pazopanib therapy requires careful consideration. |
| format | Article |
| id | doaj-art-c01b9e52dfea4acc93a90be33fdaccb3 |
| institution | Kabale University |
| issn | 2090-6684 2090-6692 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Obstetrics and Gynecology |
| spelling | doaj-art-c01b9e52dfea4acc93a90be33fdaccb32025-02-03T05:47:47ZengWileyCase Reports in Obstetrics and Gynecology2090-66842090-66922017-01-01201710.1155/2017/48016504801650Tumors Sharply Increased after Ceasing Pazopanib Therapy for a Patient with Advanced Uterine Leiomyosarcoma: Experience of Tumor FlareTerumi Tanigawa0Shintaro Morisaki1Hisanobu Fukuda2Shuichiro Yoshimura3Hisayoshi Nakajima4Kohei Kotera5Department of Obstetrics and Gynecology, Nagasaki Harbor Medical Center City Hospital, 6-39 Shinchimachi, Nagasaki-shi, Nagasaki 850-8555, JapanDepartment of Obstetrics and Gynecology, Nagasaki Harbor Medical Center City Hospital, 6-39 Shinchimachi, Nagasaki-shi, Nagasaki 850-8555, JapanDepartment of Obstetrics and Gynecology, Nagasaki Harbor Medical Center City Hospital, 6-39 Shinchimachi, Nagasaki-shi, Nagasaki 850-8555, JapanDepartment of Obstetrics and Gynecology, Nagasaki Harbor Medical Center City Hospital, 6-39 Shinchimachi, Nagasaki-shi, Nagasaki 850-8555, JapanDepartment of Obstetrics and Gynecology, Nagasaki Harbor Medical Center City Hospital, 6-39 Shinchimachi, Nagasaki-shi, Nagasaki 850-8555, JapanDepartment of Obstetrics and Gynecology, Nagasaki Harbor Medical Center City Hospital, 6-39 Shinchimachi, Nagasaki-shi, Nagasaki 850-8555, JapanPazopanib has activity in patients with soft-tissue sarcoma. We report an advanced uterine leiomyosarcoma case that suddenly worsened after cessation of pazopanib therapy. A 47-year-old woman had a primary uterine leiomyosarcoma tumor and multiple lung metastases, which progressed during her initial treatment. In subsequent treatment with pazopanib for 3 months, the sum of her tumor diameters after cessation sharply increased for two weeks. Symptoms such as dyspnea suddenly worsened also. She died of the disease one month after cessation of pazopanib therapy. Given the poor prognosis of recurrent uterine leiomyosarcoma and the rapid tumor enlargement after ending pazopanib therapy, control of this disease is especially important. Therefore, the decision to discontinue pazopanib therapy requires careful consideration.http://dx.doi.org/10.1155/2017/4801650 |
| spellingShingle | Terumi Tanigawa Shintaro Morisaki Hisanobu Fukuda Shuichiro Yoshimura Hisayoshi Nakajima Kohei Kotera Tumors Sharply Increased after Ceasing Pazopanib Therapy for a Patient with Advanced Uterine Leiomyosarcoma: Experience of Tumor Flare Case Reports in Obstetrics and Gynecology |
| title | Tumors Sharply Increased after Ceasing Pazopanib Therapy for a Patient with Advanced Uterine Leiomyosarcoma: Experience of Tumor Flare |
| title_full | Tumors Sharply Increased after Ceasing Pazopanib Therapy for a Patient with Advanced Uterine Leiomyosarcoma: Experience of Tumor Flare |
| title_fullStr | Tumors Sharply Increased after Ceasing Pazopanib Therapy for a Patient with Advanced Uterine Leiomyosarcoma: Experience of Tumor Flare |
| title_full_unstemmed | Tumors Sharply Increased after Ceasing Pazopanib Therapy for a Patient with Advanced Uterine Leiomyosarcoma: Experience of Tumor Flare |
| title_short | Tumors Sharply Increased after Ceasing Pazopanib Therapy for a Patient with Advanced Uterine Leiomyosarcoma: Experience of Tumor Flare |
| title_sort | tumors sharply increased after ceasing pazopanib therapy for a patient with advanced uterine leiomyosarcoma experience of tumor flare |
| url | http://dx.doi.org/10.1155/2017/4801650 |
| work_keys_str_mv | AT terumitanigawa tumorssharplyincreasedafterceasingpazopanibtherapyforapatientwithadvanceduterineleiomyosarcomaexperienceoftumorflare AT shintaromorisaki tumorssharplyincreasedafterceasingpazopanibtherapyforapatientwithadvanceduterineleiomyosarcomaexperienceoftumorflare AT hisanobufukuda tumorssharplyincreasedafterceasingpazopanibtherapyforapatientwithadvanceduterineleiomyosarcomaexperienceoftumorflare AT shuichiroyoshimura tumorssharplyincreasedafterceasingpazopanibtherapyforapatientwithadvanceduterineleiomyosarcomaexperienceoftumorflare AT hisayoshinakajima tumorssharplyincreasedafterceasingpazopanibtherapyforapatientwithadvanceduterineleiomyosarcomaexperienceoftumorflare AT koheikotera tumorssharplyincreasedafterceasingpazopanibtherapyforapatientwithadvanceduterineleiomyosarcomaexperienceoftumorflare |